Home' South Florida Gay News : SFGN 111815 Contents 11.18.2015 • 7
POWER TO HELP YOU BE UNDETECTABLE
ATRIPLA is the #1 prescribed
one pill, once-daily HIV treatment‡
SELECTED IMPORTANT SAFETY INFORMATION
• Some people who have taken medicines like ATRIPLA
have developed build up of lactic acid in the blood, which
can be a serious medical emergency that can lead to death.
• Some people who have taken medicines like ATRIPLA have
developed serious liver problems, with liver enlargement
and fat in the liver, which can lead to death.
• If you also have hepatitis B virus (HBV) infection and you stop
taking ATRIPLA, your hepatitis may suddenly get worse. ATRIPLA
is not approved for the treatment of HBV.
Please see below for more information about these warnings, including
signs and symptoms, and other Important Safety Information.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
With over 9 years of
Ask your doctor about ATRIPLA today.
What should I tell my healthcare provider before taking ATRIPLA?
Tell your healthcare provider if you:
• Are pregnant or planning to become pregnant: Women should not become pregnant while
taking ATRIPLA and for 12 weeks after stopping ATRIPLA.
Serious birth defects have been seen in children of women treated during pregnancy with
efavirenz, one of the medicines in ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil
fumarate). Women must use a reliable form of barrier contraception, such as a condom
or diaphragm, even if they also use other methods of birth control, while on ATRIPLA and
for 12 weeks after stopping ATRIPLA. Women should not rely only on hormone-based
birth control, such as pills, injections, or implants, because ATRIPLA may make these
• Are breastfeeding: Women with HIV should not breastfeed because they can pass HIV
and some of the medicines in ATRIPLA through their milk to the baby. It is not known if
ATRIPLA could harm your baby.
• Have kidney problems or are undergoing kidney dialysis treatment.
• Have bone problems.
• Have liver problems, including hepatitis B or C virus infection. Your healthcare provider
may want to do tests to check your liver while you take ATRIPLA or may switch you to
• Have ever had mental illness or are using drugs or alcohol
• Have ever had seizures or are taking medicine for seizures. Seizures have occurred in patients
taking efavirenz, a component of ATRIPLA, generally in those with a history of seizures. If you
have ever had seizures, or take medicine for seizures, your healthcare provider may want to
switch you to another medicine or monitor you.
What important information should I know about taking other medicines
ATRIPLA may change the effect of other medicines, including the ones for HIV-1,
and may cause serious side effects. Your healthcare provider may change your other
medicines or change their doses.
MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA
• ATRIPLA should not be taken with: Combivir® (lamivudine/zidovudine),
COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate),
EMTRIVA® (emtricitabine), Epivir® or Epivir-HBV® (lamivudine), Epzicom®
(abacavir sulfate/lamivudine), STRIBILD® (elvitegravir/cobicistat/emtricitabine/tenofovir
DF), Trizivir® (abacavir sulfate/lamivudine/zidovudine), TRUVADA® (emtricitabine/tenofovir
DF), or VIREAD® (tenofovir DF), because they contain the same or similar active ingredients
as ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate). ATRIPLA should not be
used with SUSTIVA® (efavirenz) unless recommended by your healthcare provider.
• Vfend® (voriconazole) should not be taken with ATRIPLA since it may lose its effect or
may increase the chance of having side effects from ATRIPLA.
• ATRIPLA should not be used with HEPSERA® (adefovir dipivoxil).
These are not all the medicines that may cause problems if you take ATRIPLA.
Tell your healthcare provider about all prescription and nonprescription medicines,
vitamins, or herbal supplements you are taking or plan to take.
Important Safety Information is continued on the following page.
Please see Patient Information on the following pages.
Links Archive SFGN 111115 SFGN 112515 Navigation Previous Page Next Page